Nuclear Medicine and Molecular Imaging

The Korean Society of Nuclear Medicine (대한핵의학회)
권호 표지

Different $^{18}$F-FDG Uptake According to Tumor location and Morphology of Cholangiocarcinoma and Its Clinical Implication

담관암의 위치와 형태에 따른 $^{18}$F-FDG 섭취량의 차이와 임상적 의의

  • Lee, Won-Seok (Departments of Internal Medicine, Chonbuk National University Medical School and Hospital) ;
  • Lee, Yoon-Jae (Departments of Internal Medicine, Chonbuk National University Medical School and Hospital) ;
  • Lim, Seok-Tae (Department of Nuclear Medicine, Chonbuk National University Medical School and Hospital) ;
  • Sohn, Myung-Hee (Department of Nuclear Medicine, Chonbuk National University Medical School and Hospital) ;
  • Lee, Seung-Ok (Departments of Internal Medicine, Chonbuk National University Medical School and Hospital)
  • 이원석 (전북대학교 의학전문대학원 내과학교실) ;
  • 이윤재 (전북대학교 의학전문대학원 내과학교실) ;
  • 임석태 (전북대학교 의학전문대학원 핵의학교실) ;
  • 손명희 (전북대학교 의학전문대학원 핵의학교실) ;
  • 이승옥 (전북대학교 의학전문대학원 내과학교실)
  • Published : 2009.08.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: $^{18}$F-flurodeoxyglucose (FDG) uptake on positron emission tomography (PET) scan has been found to reflect tumor aggressiveness and prognosis in various types of cancer. However, pattern of FDG uptake in biliary malignancies and its clinical significance have not been studied well. The purpose of this study was to assess the additional value of $^{18}$F-FDG PET in differential diagnosis and prognosis of cholangiocarcinoma (CC) according to the tumor location and tumor morphology. Materials and Methods: From April 2005 to May 2008, eighty two patients (M:F = 55:27, age 66.2$\pm$9.6 yrs) with CC underwent $^{18}$F-FDG PET. For semiquantitative analysis, the maximum standardized uptake value (SUV$_{max}$) was obtained from the primary tumor. The difference of SUV$_{max}$ according to the tumor location and tumor growth pattern, such as scirrhous type, nodular type, polypoid type were compared. Results: Overall sensitivity of PET scan was 81.7% in CC. SUV$_{max}$ on PET scan in intrahepatic CC was significantly higher compared to extrahepatic CC. In extrahepatic CC, polypoid type showed significantly higher SUV$_{max}$ compared to scirrhous type. Conclusion: $^{18}$F-FDG PET may have a significant impact on clinical decision-making and on the management of intrahepatic cholangiocarcinoma. And it is related to the shape of the tumor and the sensitivity of detection is higher in the mass-forming type than in the scirrhous type.

목적: 담관암의 진단과 치료 평가를 위해서 여러 영상학적 방법이 이용되나 성장 형태를 포함한 질환의 성상이 아주 다양하고 종양과 주변 조직간의 대조도가 낮은 경우 발견이 어렵고 주로 종양 부분에 대한 국소 영상을 시행하여 질병의 전신 평가에는 충분하지 못할 수 있다. 이러한 점을 보완하기 위하여 $^{18}$F-FDG PET에 대한 연구가 이루어 지고 있는데, 본 연구에서는 담관암의 발생위치와 성장형태에 따라 $^{18}$F-FDG 섭취양상의 변화와 그에 따른 임상적 의의를 알아보고자 하였다. 대상 및 방법: 2005년 4월부터 2008년 5월까지 담관암으로 진단 받고 PET/CT를 촬영한 환자를 대상으로 하였다. 위치에 따른 담관암의 분류는 간내담관암과 간외담관암으로 나누고 간외담관암은 간문부암과 원위부 담도 암으로 나누었다. 간외담관암은 다시 그 성장형태에 따라 경화형, 결절형, 용종형으로 분류하여 PET양성인 환자들 중 SUV$_{max}$를 비교하였다. 결과: 총 82명의 담도암 환자들 중PET양성을 보인 환자는 81.7%이었다. PET 양성을 보인 간내담관암 환자는 23명으로 이들의 SUV$_{max}$는 9.4$\pm$4.1로 간외담관암보다 의미있게 높았다. 용종형의 간외담관암은 9명중 모두가 PET 양성이었고, SUV$_{max}$도 10.1$\pm$7.0으로 경화형, 결절형에 비해 높았다. 결론: 본 연구의 결과를 바탕으로$^{18}$F-FDG PET은 간외담관암보다는 간내담관암을 가진 환자의 진단에 더 유용할 것으로 보이며, 간외담관암의 진단에 있어서는 담도벽을 따라 침윤성으로 발생하는 경화형보다는 종괴를 형성하는 용종형에서 더 의미있는 검사방법이 될 수 있겠다.

Keywords

References

  1. Kelloff GJ, Hoffman JM, Johnson B, Scher HI, Seigel BA, Cheng EY, et al. Progress and promise of FdDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res 2005;11:2785-808 https://doi.org/10.1158/1078-0432.CCR-04-2626
  2. Lee SO. Physiologic and pathologic experimental models for studying cholangiocytes. Korean J Hepatol 2008;14:139-49 https://doi.org/10.3350/kjhep.2008.14.2.139
  3. Lee JD, Yang WI, Park YN, Kim KS, Choi JS, Yun M, et al. Different glucose uptake and glycolytic mechanisms between hepatocellular carcinoma and intrahepatic mass-forming cholangiocarcionoma with increased $^{18}$F-FDG uptake. J Nucl Med 2005;46:1753-9
  4. Yun MJ. The role of positron emission tomography in hepatobiliary cancer. Hanyang Med Rev 2007;27:52-8
  5. Romagnlol J, Bardou M, Rahme E, Joseph L, Reinhold C, Barkun AN. Magnetic resonance cholangiopancreatography: a meta-analysis of test performance in suspected biliary disease. Ann Intern Med 2003; 139:547-57 https://doi.org/10.7326/0003-4819-139-7-200310070-00006
  6. Lazaridis KN, Gores GJ. Cholangiocarcinoma. Gastroenterology 2005;128:1655-67 https://doi.org/10.1053/j.gastro.2005.03.040
  7. Keiding S, Hansen SB, Rasmussen HH, Gee A, Kruse A, Roelsqaard K, et al. Detection of cholangiocarcinoma in primary sclerosing cholangitis by positron emission tomography. Hepatology 1998;28:700-6 https://doi.org/10.1002/hep.510280316
  8. Petrowsky H, Wildbrett P, Husarik DB, Hany TF, Tam S, Jochum W, et al. Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma. J Hepatol 2006;45:43-50 https://doi.org/10.1016/j.jhep.2006.03.009
  9. Alpini G, Roberts S, Kuntz SM, Ueno Y, Gubba S, Podila PV, et al. Morphological, molecular, and functional heterogeneity of cholangiocytes from normal rat liver. Gastroenterology 1996;110:1636-43 https://doi.org/10.1053/gast.1996.v110.pm8613073
  10. Alpini G, Ulrich C, Roberts S, Phillips JO, Ueno Y, Podila PV, et al. Molecular and functional heterogeneity of cholangiocytes from rat liver after bile duct ligation. Am J Physiol 1997;272:289-97 https://doi.org/10.1152/ajpgi.1997.272.2.G289
  11. Fritscher-Ravens A, Bohuslavizki KH, Broering DC, Jenicke L, Schafer H, Buchert R, et al. FDG PET in the diagnosis of Hilar cholangiocarcionoma. Nucl Med Commun 2001;22:1277-85 https://doi.org/10.1097/00006231-200112000-00002
  12. Kluge R, Schimidt F, Cara K, Barthel H, Hesse S, Georgi P, et al. Positron emission tomography with [$^{18}$F$]fluoro-2-deoxy-I)-glucose for diagnosis and staging of bile duct cancer. Hepatology 2001;33:1029-35 https://doi.org/10.1053/jhep.2001.23912
  13. Kato T, Tsukamoto E, Kuge Y, Katoh C, Nambu T, Nobuta A, et al. Clinical role of $^{18}$F-FDG PET for initial staging of patients with extrahepatic bile duct cancer. Eur J Nucl Med Mol Imaging 2002;29:1047-54 https://doi.org/10.1007/s00259-002-0852-z
  14. Choi BI, Lee JH, Han MC, Kim SH, Yi JG, Kim CW. Hilar cholangiocarcinona: comparative study with sonography and CT. Radiography 1989;172:682-92
  15. Kim YJ, Yun MJ, Lee WJ, Kim KS, Lee JD. Usefulness of $^{18$F-FDG PET in Intrahepatic cholangiocarcionoma. Eur J Nucl Med Mol Imaging 2003;30:1467-72 https://doi.org/10.1007/s00259-003-1297-8
  16. De Gronen PC, Gores GJ, Larusso NF, Gunderson LL, Nagomey DM. Biliary tract cancers. N Engl J Med 1999;341:1368-77 https://doi.org/10.1056/NEJM199910283411807